Journal of Ophthalmic Inflammation and Infection

Table 10 Flare score by treatment and visit (ITT)

From: Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

		Baseline	Day 1	Day 3	Day 7	Day 14
Nepafenac group	Mean	0.0	0.9	0.5	0.3	0.1
	Std	0.0	0.6	0.6	0.5	0.3
	N	106	105	105	105	105
	Min	0	0	0	0	0
	Max	0	2	2	2	2
Placebo group	Mean	0.0	0.9	0.7	0.8	0.6
	Std	0.0	0.5	0.7	0.8	0.8
	N	105	105	105	105	105
	Min	0	0	0	0	0
	Max	0	2	3	3	3
P value		N/A	0.5793	0.0041	<0.0001	<0.0001

Baseline P value is from t test; non-baseline P values are LSMeans by visit; test = repeated measure ANOVA, main effect of treatment P < 0.0001; treatment by visit interaction P < 0.0001
Min minimum, Max maximum, Std standard deviation

Back to article page